Precigen's PAPZIMEOS Generates $3.4M Q4 Revenue, Gains J-Code, Targets Cash Flow Break-Even
Summary
Precigen reported full year 2025 financial results, highlighting $3.4 million in net product revenue for PAPZIMEOS in the fourth quarter of 2025, its first partial quarter of commercial sales. The company announced strong commercial momentum for PAPZIMEOS, including a significant increase in demand in Q1 2026 and the assignment of a permanent J-code (J3404) effective April 1, 2026, which will streamline reimbursement and patient access. With $100.4 million in cash, cash equivalents, and investments as of December 31, 2025, Precigen expects to fund operations to cash flow break-even. These updates confirm the company's successful transition to a commercial-stage entity with a clear path to financial sustainability, making this a material positive development for traders.
At the time of this announcement, PGEN was trading at $2.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $1.11 to $5.47. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.